If this is your first visit, be sure to
check out the FAQ by clicking the
link above. You may have to register
before you can post: click the register link above to proceed. To start viewing messages,
select the forum that you want to visit from the selection below.

I've been PM'd by several, so let me come clean.

To say I was disapointed in the SCOTUS ruling would be an enormous understatement. I had hoped it would be nullified totally, so we could move on to correcting all the other ills we are facing.

To consider Obamacare 'healthcare' is to be incredibly naive. American 'healthcare' and it's funding has been bastardized for many decades. Obamacare is just the latest, and probably the most final. The damage this program will cause, should it become fully implemented, with be the final load of bricks to crush the camel's back, and kill a nation's future.

Why is this so important to me? Because I do have some skin in this game. A couple of years ago, I was diagnosed with myelodisplastic syndrome (MDS). It usually culminates in lukemia. My malady has morphed into bone marrow cancer, and while it seems to be held in check with chemo at this time, it is incurable, thus terminal.

There has been some great strides made in this field through biotechnology that I fear Obamacare would tax out of existance. So, like many others, we individually get involved when our ox is being gored. Now you know why I'm against this latest atrosity being foisted upon the American people. Here's further info.:

UB

The Race between Science and Politics

Ray Blanco

“There are two consequences in history; an immediate one, which is instantly recognized, and one in the distance, which is not at first perceived.”

— Frederic Bastiat

Last week, the big news was the Supreme Court’s ruling upholding Obamacare. Stocks, already down for the day, plummeted further on the news. Emerging biotechnology companies were among the hardest hit...briefly. Most biotech stocks have already re-bounded from the one-day Obamacare selloff and have soared to new multi-year highs.

But that selloff, brief though it was, illustrated a very real battle that is just now unfolding. It is a battle between science and politics — a battle between innovators and price-fixers. This campaign promises to be a difficult and prolonged one, but biomedical innovation will emerge triumphant.

Those who oppose Obamacare rail against the program’s price tag and against the fact that it restricts the freedom of choice of American citizens. These are the most immediate issues, and they are important. The downside, however, doesn’t end there.

For decades, the US has been a world leader in biomedical innovation. From 2001-2011, for example, I count 15 Nobel Prizes in physiology or medicine that have been awarded to scientists working in the US, whether native-born or otherwise.

Today, the bulk of global biomedical research takes place in the US.

If we discount academic research and focus solely on privately funded commercial research and development, America’s share is even higher. Often, when I visit labs or speak with biotechnology innovators, I can’t help but notice how many of the researchers are from overseas and choose to pursue their careers here. There is a reason for that, and that has been the relatively free US health care market.

This bill, however, could be bad for biotechnology development. For example, it contains a special tax on medical devices — and much of the innovation taking place in the market is in improved diagnostic devices and gene-sequencing equipment. We also have to consider what effect increased government control will have on biomedical innovation.

Faced with growing deficits that this bill will only exacerbate, politicians will focus on cutting costs, rather than funding basic research. Rationing and capping compensation for new, lifesaving technologies will become inevitable. A breakthrough therapy could be seen as an expense by a bean-counting government panel.

Think of all of the lifesaving advances in biotechnology of the past decades. These were developed by private companies because they expected a profitable market for their inventions and discoveries. Reduce the incentive to innovate and what will the technological landscape look like in a few years, all other factors being equal?

A growing army of bureaucrats and regulations threaten to reduce the pace of new medical technologies right when we are on the verge of mind-boggling lifesaving breakthroughs. Enormous advances are being made in treating disease at the genetic and molecular levels, and they show unbelievable promise in treating cancer, cardiovascular disease and even aging itself.

We are in a race. On the one hand, we have scientific advance, unraveling the mysteries of life and developing revolutionary new therapies. On the other, we have politicians trying to lock everything down into a stasis, whether they know it or not.

Nevertheless, the biotech revolution will continue. The coming breakthroughs will be so huge that no government will be able to stop them. Investors enabling them will earn fortunes. A substantial increase in life spans will bankrupt entitlement programs. New technologies will accelerate a fundamental transformation of the economy. This has been the case all through history. This trend is your friend.

Regards,

Ray Blanco,
for The Daily Reckoning

Editor’s Note: Ray’s dedication to this type of research is nothing short of amazing, and we can think of few people we’d trust more when it comes to keeping track of these trends. So when he says to make this trend our friend, we’re inclined cozy up to it and buy it a beer or two.